Asahi Kasei reports developments across a diversified global business that includes healthcare, materials, electronic components, and hydrogen-related technologies. News commonly covers pharmaceutical pipeline expansion, specialty pharmaceutical acquisitions, antiviral and autoimmune-disease programs, and subsidiary activity involving Veloxis Pharmaceuticals, Asahi Kasei Therapeutics, and Asahi Kasei Pharma.
Company updates also include Asahi Kasei Microdevices' magnetic-sensor and photonic technology work, chlor-alkali electrolysis products such as electrolyzer cells, ion-exchange membranes, and electrodes, and Aqualyzer™ alkaline-water electrolyzer deployments for hydrogen production. Recurring themes include research collaborations, license agreements, clinical and regulatory disclosures, material agreements, capital-structure updates, and operating and financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Asahi Kasei and Microwave Chemical have initiated a joint project to commercialize a chemical recycling process for polyamide 66 (PA66) using microwave technology, launched in April 2023. This process involves depolymerizing PA66 to directly extract high-yield monomers hexamethylenediamine (HMD) and adipic acid (ADA) with low energy consumption. The project aims to reduce greenhouse gas emissions in PA66 production, leveraging Microwave Chemical's PlaWave™ technology. Laboratory studies confirmed successful depolymerization of PA66, and plans for bench-scale equipment are underway at the Osaka Factory to further validate the process through a small-scale demonstration trial in fiscal 2024. A decision on commercialization will follow by fiscal 2025.
Asahi Kasei Bioprocess America and GeminiBio have formed a strategic partnership to enhance inline buffer formulation (IBF) in the biopharmaceutical industry. This collaboration aims to streamline buffer management, thereby reducing production bottlenecks and costs, increasing productivity, and improving medication accessibility globally. The partnership, initiated in March 2023, combines Asahi Kasei's MOTIV IBF™ system with GeminiBio's pre-mixed concentrates, creating a comprehensive solution for biopharmaceutical manufacturers. The synergy is expected to foster innovation and set new industry standards, benefiting manufacturers by simplifying processes and ensuring timely buffer production.